Valneva SE (NAS:VALN)
$ 3.9299 -0.0301 (-0.76%) Market Cap: 321.47 Mil Enterprise Value: 368.73 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 64/100

Nine Months 2019 Valneva SE Earnings Call Transcript

Oct 31, 2019 / 01:00PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Valneva 9-Month 2019 Financial Results Conference Call. (Operator Instructions) I must advise you that this conference is being recorded today, Thursday, 31st of October 2019.

I would now like to hand the conference over to your speaker today, Thomas Lingelbach. Please go ahead, sir.

Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO

Thank you so much. Good day to everyone. It's a pleasure for us to present today our 9-month 2019 financial results and to give you some updates on our strong R&D execution and general business.

With that, let me draw your attention to Page #4 of the presentation. So first of all, of course, the biggest news of the day is that we have raised our 2019 full year product sales guidance following a strong 9-month result and, more importantly, even we have to report nice and significant R&D milestones and progression.

On our lead program in R&D, our Lyme vaccine, which is the only clinical-stage

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot